Myriad sues competitors over genetic testing

The Supreme Court invalidated two of the company’s gene patents last month

Just weeks after the end of its Supreme Court battle over gene patentability, Myriad Genetics has launched another patent fight against two competitors that are offering genetic testing for breast cancer risk.

Until the Supreme Court’s June 13 ruling, Myriad held patents on the genes BRCA1 and BRCA2, which are associated with a heightened risk of hereditary breast and ovarian cancer. The high court invalidated those patents—ruling that naturally occurring DNA is not patentable—but it upheld the patentability of synthetic DNA.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.